MX2018007511A - Compuestos de alquinil dihidroquinolina sulfonamida. - Google Patents
Compuestos de alquinil dihidroquinolina sulfonamida.Info
- Publication number
- MX2018007511A MX2018007511A MX2018007511A MX2018007511A MX2018007511A MX 2018007511 A MX2018007511 A MX 2018007511A MX 2018007511 A MX2018007511 A MX 2018007511A MX 2018007511 A MX2018007511 A MX 2018007511A MX 2018007511 A MX2018007511 A MX 2018007511A
- Authority
- MX
- Mexico
- Prior art keywords
- dihydroquinoline
- alkynyl
- compounds
- sulfonamide compounds
- present
- Prior art date
Links
- -1 Alkynyl dihydroquinoline sulfonamide compounds Chemical class 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108010052164 Sodium Channels Proteins 0.000 abstract 2
- 102000018674 Sodium Channels Human genes 0.000 abstract 2
- 206010011224 Cough Diseases 0.000 abstract 1
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 abstract 1
- 208000003251 Pruritus Diseases 0.000 abstract 1
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 abstract 1
- 208000027520 Somatoform disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000007803 itching Effects 0.000 abstract 1
- 208000027753 pain disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona compuestos de la Fórmula I, (ver Fórmula) y sal farmacéuticamente aceptables de los mismos que son inhibidores de canales de sodio abiertos por voltaje, en particular Nav1.7. Los compuestos son útiles para el tratamiento de enfermedades asociadas con actividad de canales de sodio tal como trastornos de dolor, tos, y comezón. También se proporcionan composiciones farmacéuticas que contienen compuestos de la presente invención.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562269533P | 2015-12-18 | 2015-12-18 | |
| PCT/US2016/067622 WO2017106872A1 (en) | 2015-12-18 | 2016-12-19 | Alkynyl dihydroquinoline sulfonamide compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018007511A true MX2018007511A (es) | 2018-09-18 |
| MX378012B MX378012B (es) | 2025-03-10 |
Family
ID=57758770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018007511A MX378012B (es) | 2015-12-18 | 2016-12-19 | Compuestos de alquinil dihidroquinolina sulfonamida. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10729684B2 (es) |
| EP (1) | EP3390393A1 (es) |
| JP (1) | JP6985271B2 (es) |
| AU (1) | AU2016369653B2 (es) |
| CA (1) | CA3008485C (es) |
| MA (1) | MA44066A (es) |
| MX (1) | MX378012B (es) |
| WO (1) | WO2017106872A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021007425A (es) * | 2018-12-26 | 2021-08-05 | Raqualia Pharma Inc | Derivados heterociclicos como bloqueadores de nav1.7 y nav1.8. |
| EP4073037A4 (en) * | 2019-12-11 | 2023-12-27 | Duke University | VOLTAGE-DEPENDENT SODIUM 1.7 CHANNEL SMALL MOLECULE INHIBITORS AND METHODS OF USE |
| MX2022015857A (es) * | 2020-06-10 | 2023-01-24 | Amgen Inc | Compuestos de dihidroquinolin sulfonamida de heteroalquilo. |
| JP7739051B2 (ja) * | 2020-06-10 | 2025-09-16 | アムジエン・インコーポレーテツド | シクロブチルジヒドロキノリンスルホンアミド化合物 |
| JP2021195367A (ja) * | 2020-06-10 | 2021-12-27 | アムジエン・インコーポレーテツド | シクロプロピルジヒドロキノリンスルホンアミド化合物 |
| US20250154105A1 (en) * | 2021-08-12 | 2025-05-15 | Tyk Medicines, Inc. | Polycyclic compound and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| US8101647B2 (en) | 2008-10-17 | 2012-01-24 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| WO2013122897A1 (en) * | 2012-02-13 | 2013-08-22 | Amgen Inc. | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors |
| WO2013134518A1 (en) | 2012-03-09 | 2013-09-12 | Amgen Inc. | Sulfamide sodium channel inhibitors |
| WO2014201173A1 (en) * | 2013-06-12 | 2014-12-18 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
-
2016
- 2016-12-19 JP JP2018531540A patent/JP6985271B2/ja active Active
- 2016-12-19 CA CA3008485A patent/CA3008485C/en active Active
- 2016-12-19 US US16/062,602 patent/US10729684B2/en active Active
- 2016-12-19 EP EP16823450.8A patent/EP3390393A1/en active Pending
- 2016-12-19 MX MX2018007511A patent/MX378012B/es unknown
- 2016-12-19 AU AU2016369653A patent/AU2016369653B2/en active Active
- 2016-12-19 MA MA044066A patent/MA44066A/fr unknown
- 2016-12-19 WO PCT/US2016/067622 patent/WO2017106872A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP6985271B2 (ja) | 2021-12-22 |
| MA44066A (fr) | 2018-10-24 |
| AU2016369653B2 (en) | 2021-02-04 |
| CA3008485C (en) | 2023-08-01 |
| AU2016369653A1 (en) | 2018-07-05 |
| WO2017106872A1 (en) | 2017-06-22 |
| MX378012B (es) | 2025-03-10 |
| CA3008485A1 (en) | 2017-06-22 |
| JP2018537505A (ja) | 2018-12-20 |
| EP3390393A1 (en) | 2018-10-24 |
| US10729684B2 (en) | 2020-08-04 |
| US20180369226A1 (en) | 2018-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY35612A (es) | Compuestos de sulfonamida bicíclicos como inhibidores de los canales de sodio | |
| ECSP19052302A (es) | Derivados de benzooxazol como inmunomoduladores | |
| CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| CO2018011064A2 (es) | Inhibidores de bromodominios | |
| MX379155B (es) | Compuestos que inhiben la proteína mcl-1. | |
| JOP20190229A1 (ar) | مركبات تثبط بروتين mcl-1 | |
| SA518391624B1 (ar) | Ror- منظمات جاما | |
| MX383856B (es) | Compuestos y composiciones para inhibir la actividad de shp2. | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| MX2018007511A (es) | Compuestos de alquinil dihidroquinolina sulfonamida. | |
| GT201600147A (es) | Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2 | |
| ECSP16005566A (es) | Sulfonamidas como moduladores de canales de sodio | |
| PH12015502004A1 (en) | Tetracyclic bromodomain inhibitors | |
| CO2018007436A2 (es) | Compuestos de dihidroquinolinsulfonamida de alquilo | |
| BR112016026552A8 (pt) | derivados de carboxamida, seus usos, composição farmacêutica, e combinação | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| CL2017002229A1 (es) | Inhibidores de bace1. | |
| CL2020002398A1 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") | |
| EA201992303A1 (ru) | СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1 | |
| BR112017020917A2 (pt) | derivados de ácido biliar como agonistas de fxr/tgr5 e seus métodos de uso |